Current Editions
RevMed maps its next RAS frontier
Poised to overhaul PDAC care, RevMed’s longer-term vision spans catalytic inhibition, immune modulation and disease interception
Product Development
Product Development
Cytokinetics scores late-stage win in non-obstructive HCM as BMS plans Camzyos restart
BioCentury’s Clinical Report April 28–May 5
Emerging Company Profile
Cytospire: Broadening tumor killing with pan-γδ T cell engagers
London-based biotech is advancing toward the clinic with a new $83M series A round
Data Byte
Europe’s Phase I trials see Spain, U.K. lead hot spots
Bio€quity Europe preview: Scene Setter analyzes European Phase I trials from 2021-25
At least five PDUFA dates on FDA’s May docket
One new product via 505(b)(2), plus four label expansions
BioCentury ISSN 1097-7201